Hematology & Oncology
The Sixth International Symposium on Ovarian Cancer and Other Gynecologic Malignancies will provide participants with cutting-edge information on the screening, diagnosis, and treatment of these diseases. This symposium will focus on clinical and translational research in the areas of ovarian, uterine, and endometrial cancers, discussing not only standards of care and current guidelines but also the most promising novel chemotherapeutics and targeted agents. Controversies in combined modality approaches to and chemotherapeutic management of ovarian cancers as well as issues revolving around staging and treatment strategies for endometrial cancers will be debated. Didactic lectures, case-based discussions, and debates will provide participants with ample opportunities to learn from and interact with key opinion leaders in the field. This educational program is directed toward medical, gynecologic, surgical, and radiation oncologists. Fellows, oncology nurses, oncology physician assistants, and pharmacists who are interested in the treatment of ovarian cancer and other gynecologic malignancies are also invited to attend.
This two-day workshop will address the need to integrate quality improvement and safety into medical education. Designed for health profession educators, this workshop will disseminate the knowledge and tools necessary to successfully implement QI and safety education in undergraduate medical education (UME), graduate medical education (GME), continuing medical education (CME), and allied health schools.
The Tenth International Congress on Genitourinary Malignancies will provide a comprehensive review of current therapeutic strategies for the treatment of all stages of kidney, bladder, and prostate cancers, including clinical and molecular disease characterization, prevention, prognostication, multimodality management of disease, and new therapeutic agents. Interactive panel discussions and case-based vignettes will provide practical clinical context for the interpretation of the presented trial data. Faculty recommendations and an interactive tumor board discussion will aid in transitioning treatment standards to individualized care in the practice setting. Participants will be able to apply the latest advances in the treatment of genitourinary malignancies to their daily practice and discuss future directions in research and clinical trials.
Overview and Purpose
The 10th International Congress on the Future of Breast Cancer is an educational and scientific meeting that focuses on the clinical implications of breast cancer genetic and phenotypic subtyping. New data and promising studies that provide information about how to optimally individualize breast cancer therapy will be discussed, and controversial issues will be debated. In addition, strategies for optimizing the use of endocrine therapy, conventional chemotherapy, and targeted therapies will be presented, and evolving diagnostic approaches to identify the driving mutations or pathways in breast cancer will be thoroughly discussed along with the therapies targeting those mutations. Controversial issues in the surgical and radiotherapeutic management of breast cancer will also be discussed and debated. The format will include didactic sessions, question-and-answer panel discussions, and ample time for participant interaction with faculty.
This educational activity is directed toward medical oncologists interested in the treatment of patients with breast cancer. Surgical and radiation oncologists, fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to attend.
At the conclusion of this congress, you should be able to:
Determine optimal surgical care for patients with breast cancer
Incorporate recent advances in radiation therapy into the treatment of patients with breast cancer
Integrate biomarkers, genomic assays, and other risk assessment tools into treatment decision making for breast cancer
Employ optimal strategies for endocrine therapy and management of bone health for patients with hormone receptor–positive breast cancer
Identify appropriate strategies for the use of cytotoxic agents in the treatment of patients with early-stage and advanced/refractory breast cancer
Design treatment strategies for patients with HER2-overexpressing breast cancer, including novel agents, combinatorial therapies, and options for patients who progress on standard therapy
Utilize targeted agents in the treatment of HER2– breast cancer
Select eligible patients with breast cancer for promising clinical trials
This activity is presented by Physicians’ Education Resource in conjunction with the West Virginia Oncology Society.
The West Virginia Oncology Society Annual CME Meeting is designed to educate community physicians on the state-of-the-art clinical management of a wide variety of solid and hematologic malignancies. Lectures will highlight cutting-edge information and emerging treatment strategies for specific tumor types, including head and neck cancer, non–small-cell lung cancer, gastrointestinal malignancies, genitourinary malignancies, breast cancer, chronic lymphocytic leukemia, and multiple myeloma, using conventional didactic modalities in addition to practical case-based presentations. This meeting presents an opportunity for continuous dialogue and interaction between academic thought leaders and community oncologists.